CERo Therapeutics Holdings, Inc. (CERO)
OQB · Healthcare · Biotechnology
$0.01
-8.33%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$496,236.47
Shares Outstanding
45.1M
Exchange
OQB
Currency
USD
About CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -5.4M | -4.4M | -4.4M | -4.8M |
| Net Income | -5.4M | -4.9M | -4.5M | -5.9M |
| Diluted EPS | $-61.71 | $-9.10 | $nan | $-0.20 |
Annual Financials
| Metric | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -11.6M | -12.0M | -7.7M | -19.3M |
| Net Income | -10.6M | -11.8M | -7.3M | -19.9M |
| Diluted EPS | $-2,345.98 | $-2,610.71 | $-1,416.55 | $-22.58 |